Heartflow (NASDAQ:HTFL) Research Coverage Started at Wells Fargo & Company

Wells Fargo & Company assumed coverage on shares of Heartflow (NASDAQ:HTFL) in a research report sent to investors on Wednesday morning, Marketbeat.com reports. The firm issued an overweight rating and a $38.00 price target on the stock.

Other research analysts also recently issued reports about the stock. Canaccord Genuity Group raised their price target on shares of Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. JPMorgan Chase & Co. raised their target price on shares of Heartflow from $36.00 to $40.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Finally, Stifel Nicolaus increased their price target on Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

Heartflow Price Performance

Shares of HTFL opened at $29.87 on Wednesday. The company has a market capitalization of $2.54 billion and a PE ratio of -16.50. The stock’s fifty day moving average price is $30.71. Heartflow has a 12-month low of $25.38 and a 12-month high of $41.22.

Insider Transactions at Heartflow

In other Heartflow news, Director Jeffrey C. Lightcap bought 40,000 shares of the stock in a transaction that occurred on Tuesday, December 16th. The shares were purchased at an average cost of $26.34 per share, for a total transaction of $1,053,600.00. Following the transaction, the director directly owned 40,000 shares in the company, valued at $1,053,600. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. UBS Group AG raised its stake in shares of Heartflow by 228.8% during the fourth quarter. UBS Group AG now owns 501,165 shares of the company’s stock valued at $14,609,000 after purchasing an additional 348,753 shares in the last quarter. Quent Capital LLC bought a new stake in shares of Heartflow during the 4th quarter worth about $583,000. Vanguard Group Inc. raised its position in shares of Heartflow by 8.8% during the 4th quarter. Vanguard Group Inc. now owns 1,580,313 shares of the company’s stock worth $46,066,000 after buying an additional 128,400 shares in the last quarter. Perpetual Ltd bought a new position in shares of Heartflow in the fourth quarter valued at approximately $459,000. Finally, SG Americas Securities LLC acquired a new position in shares of Heartflow during the fourth quarter valued at approximately $312,000.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.